Elucidating the effects of Olfactory Receptor 78 on blood pressure and renin release
阐明嗅觉受体 78 对血压和肾素释放的影响
基本信息
- 批准号:9611111
- 负责人:
- 金额:$ 4.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-19 至 2021-07-18
- 项目状态:已结题
- 来源:
- 关键词:AddressAntihypertensive AgentsBackBindingBlood PressureCalciumCell LineChemicalsComplexCyclic AMPDiseaseExhibitsFamilyFutureG-Protein-Coupled ReceptorsGTP-Binding Protein alpha Subunits, GsHypotensionIn VitroJuxtaglomerular ApparatusKidneyKnock-outKnockout MiceLaboratoriesLinkMediatingMusNosePathway interactionsPeripheralPharmacologyPhenotypePlasmaPlayProcessProductionPropionatesReninRoleSignal PathwaySignal TransductionSmell PerceptionSmooth Muscle MyocytesStressTissuesVascular Smooth MuscleVolatile Fatty AcidsWorkblood pressure regulationcell immortalizationcell typedetectorgut microbiotahigh salt diethost microbiotain vitro Modelin vivoin vivo Modelinhibitor/antagonistinsightkidney cellmouse modelnovelolfactory receptorreceptorrecombinase-mediated cassette exchangeresponsetool
项目摘要
Project Summary
Recent studies in our laboratory have demonstrated that olfactory receptor 78 (Olfr78) is a short chain fatty
acid (SCFA) receptor that plays a critical role in the modulation of blood pressure. Olfr78 modulates renin
release in response to SCFA’s such as propionate, which are produced by the gut microbiota. To date we have
shown that Olfr78 is expressed in the renal juxtaglomerular apparatus (JGA), and that Olfr78KO mice are
defective in their ability to release renin in response to SCFAs. In addition however, Olfr78 is also expressed in
vascular smooth muscle cells of the peripheral vasculature; where it could also contribute to blood pressure
control. Full body Olfr78 null mice exhibit lowered blood pressure at baseline, and we hypothesize that this
hypotension is primarily mediated by Olfr78 signaling in the JGA. To definitively identify the Olfr78-expressing
cell type which is primarily responsible for the hypotensive phenotype, we will use a recently created mouse
model where Olfr78 is selectively knocked out in the JGA using a Cre-lox system (Olfr78 JGA KO).
Characterization of these tissue specific knockout mice will determine the contribution of JGA-localized Olfr78
to the hypotensive phenotype observed in the full body knockout, as well as expand upon Olfr78’s role in the
kidney. Furthermore, while it is known that Olfr78 is a G-protein coupled receptor, the precise signaling
pathway linking SCFA binding and renin release has not yet been shown. Prior studies show that cAMP
production leads to renin release in the JGA, and that this release is inhibited by the elevation of cytosolic
calcium levels. To establish the link between Olfr78 and cAMP mediated renin release, plan to utilize a stably
expressing Olfr78 immortalized JGA cell line. This cell line will be a valuable tool in probing the mechanism
underlying Olfr780mediated renin secretion in vitro. The subsequent findings can then be applied back to the in
vivo model to better understand how a single OR can impact the complex process of blood pressure
regulation. I hypothesize that Olfr78 in the JGA plays a significant role in the regulation of blood
pressure via renin release, and that this release is mediated via a Gsα dependent cAMP pathway. To
address this hypothesis, I propose the following aims. Aim 1: To identify which Olfr78 expressing cell type is
responsible for baseline hypotension seen in the full body Olfr78 knockout. I will characterize a mouse model
where Olfr78 has been selectively knocked out in the JGA using cre-lox technology, looking specifically at
renin levels and blood pressure at baseline and under hypertensive stress. Aim 2: To determine how Olfr78
activation leads to renin release in vivo, we will elucidate the mechanism of renin release using an in vitro
model. Using an immortalized mouse kidney cell line, we will use various pharmacological inhibitors to probe
the necessary components of the signaling cascade required for Olfr78 mediated renin release. Together,
these studies will reveal new insights into a novel pathway of blood pressure regulation.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian Poll其他文献
Brian Poll的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
The role of antihypertensive agents in renal and vascular complications in a model of hypertension and diabetes
抗高血压药物在高血压和糖尿病模型中肾脏和血管并发症中的作用
- 批准号:
nhmrc : 145854 - 财政年份:2001
- 资助金额:
$ 4.45万 - 项目类别:
NHMRC Postgraduate Scholarships
APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
利尿钠和抗高血压药物的治疗方法
- 批准号:
6125791 - 财政年份:1997
- 资助金额:
$ 4.45万 - 项目类别:
APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
利尿钠和抗高血压药物的治疗方法
- 批准号:
2487342 - 财政年份:1997
- 资助金额:
$ 4.45万 - 项目类别:
APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
利尿钠和抗高血压药物的治疗方法
- 批准号:
2839029 - 财政年份:1997
- 资助金额:
$ 4.45万 - 项目类别:
APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
利尿钠和抗高血压药物的治疗方法
- 批准号:
6330091 - 财政年份:1997
- 资助金额:
$ 4.45万 - 项目类别:
Antihypertensive Agents of Kudzu: Possible Chemical Utilization of a Southeastern Pest Vine
葛根的抗高血压剂:东南部害虫藤蔓的可能化学利用
- 批准号:
7905238 - 财政年份:1979
- 资助金额:
$ 4.45万 - 项目类别:
Standard Grant














{{item.name}}会员




